NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $2.71 +0.03 (+1.12%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.70 -0.01 (-0.37%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Protalix BioTherapeutics Stock (NYSE:PLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PLX alerts:Sign Up Key Stats Today's Range$2.64▼$2.7250-Day Range$2.22▼$2.8452-Week Range$1.60▼$3.19Volume947,256 shsAverage Volume911,510 shsMarket Capitalization$218.35 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops recombinant therapeutic proteins using its proprietary ProCellEx plant-cell-based protein expression platform. The platform is designed to produce complex proteins in genetically engineered plant cells and supports the development of enzyme replacement therapies and other biologic medicines. The company’s products include Elfabrio (pegunigalsidase alfa-iwxj), an enzyme replacement therapy for adults with Fabry disease, and Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease type 1. Protalix has commercialized these products through collaborations, including arrangements with Chiesi Farmaceutici for Elfabrio and Pfizer for Elelyso in certain markets. The company is also advancing additional product candidates for rare diseases and other conditions. Founded in 1993, Protalix is based in Carmiel, Israel, and serves international markets through regulatory approvals and commercial partnerships. Its research, manufacturing and development activities are focused on applying plant-cell-based production technology to biologic medicines for patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Protalix BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScorePLX MarketRank™: Protalix BioTherapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 510th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialProtalix BioTherapeutics has a consensus price target of $12.00, representing about 342.8% upside from its current price of $2.71.Amount of Analyst CoverageProtalix BioTherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,000.00% Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is -20.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is -20.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PLX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by Institutions16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLX Stock News HeadlinesProtalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comProtalix BioTherapeutics to Participate in Upcoming September 2026 Investor ConferencesSeptember 8, 2026 | prnewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 3 at 1:00 AM | Stansberry Research (Ad)Protalix (PLX) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comPLX: Elfabrio estimates upAugust 13, 2026 | msn.comProtalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approvalAugust 12, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business ResultsAugust 12, 2026 | finanznachrichten.deSee More Headlines PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.80 at the start of the year. Since then, PLX shares have increased by 50.6% and is now trading at $2.71. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) announced its earnings results on Friday, May, 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative trailing twelve-month return on equity of 30.89%. When did Protalix BioTherapeutics' stock split? Shares of Protalix BioTherapeutics reverse split on Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protalix BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/09/2025Today10/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PLX's financial health is in the Green zone, according to TradeSmith. PLX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:PLX CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees226Year Founded1994Price Target and Rating Average Price Target for Protalix BioTherapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+342.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.23 Trailing P/E RatioN/A Forward P/E Ratio271.00 P/E GrowthN/ANet Income$8.31 million Net Margins-21.03% Pretax Margin-21.00% Return on Equity-30.89% Return on Assets-11.74% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.27 Sales & Book Value Annual Sales$80.62 million Price / Sales2.71 Cash Flow$0.15 per share Price / Cash Flow17.80 Book Value$0.47 per share Price / Book5.77Miscellaneous Outstanding Shares80,572,000Free Float68,995,000Market Cap$218.35 million OptionableOptionable Beta-0.09 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:PLX) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
